Hims & Hers Health, a prominent telehealth platform known for its personalized health and wellness solutions, announced on Wednesday its ambitious foray into the burgeoning market of longevity treatments with the launch of its "Peptides+" platform. This new initiative will initially offer five formulations of peptides and other longevity treatments, all compounded in the U.S. Crucially, none of these specific compounded products have received approval from the Food and Drug Administration (FDA), a detail that immediately positions the company at the forefront of a complex and evolving regulatory landscape. Despite the lack of official regulatory approval, Hims & Hers emphasized that these offerings are authorized by law and formulated by pharmacies adhering to rigorous quality standards and state board of pharmacy licensing and inspection.

The announcement arrives amidst a backdrop of increasing consumer interest in peptides, short chains of amino acids that enthusiasts claim offer benefits ranging from enhanced muscle growth and rapid injury recovery to anti-aging effects. This popularity has surged, particularly among fitness and longevity communities, even as robust human clinical trials supporting many of these claims remain largely absent. Hims & Hers itself acknowledged the inherent uncertainty surrounding this growing space, stating that it has "more to learn about how best to use the peptides and how effective they are." This candid admission underscores the pioneering, yet potentially precarious, nature of its new venture.

Navigating a Shifting Regulatory Landscape

The company’s ability to legally introduce these unapproved compounds into the market stems from a significant shift in federal oversight. In October of the previous year, the Health and Human Services (HHS) Department issued a policy statement indicating that the FDA would not take enforcement action against licensed pharmacies, federal facilities, or physicians that compound and dispense six specific unapproved peptides. This policy is a temporary measure, intended to remain in effect while formal rules regarding these compounds are under review. It effectively allows these entities to offer peptides that are not yet on the FDA’s official list of ingredients compounding pharmacies are permitted to use, without equating to formal FDA approval of the substances themselves.

This policy shift represents a notable reversal from an earlier decision in 2023 by the Biden administration, wherein the FDA had restricted compounding pharmacies from producing popular peptide formulations due to a range of concerns including safety, impurity, and the potential for adverse immune reactions. The changing regulatory stance highlights the ongoing debate within federal agencies regarding access to these compounds. Notably, HHS Secretary Robert F. Kennedy Jr. has publicly expressed support for broader access to peptides, identifying himself as a "big fan" of the treatments and arguing that previous restrictions were inadvertently pushing Americans towards potentially unsafe products obtained from overseas markets. Kennedy has also shared his personal experience using BPC-157, a peptide Hims plans to offer in the future, to treat a muscle injury.

Initial Offerings and Future Expansion

The initial rollout of Hims & Hers’ Peptides+ platform includes several compounded formulations targeting various aspects of health and longevity. Among them is sermorelin, a peptide known to stimulate growth-hormone release, which is marketed for its potential benefits in recovery, body composition, and anti-aging. Another key offering is glutathione, a peptide promoted for its anti-aging properties and athletic recovery, though its efficacy, particularly for widely marketed uses like skin whitening, has been questioned by studies and regulatory bodies. The platform also introduces nicotinamide adenine dinucleotide (NAD+), a crucial coenzyme involved in cellular metabolism, touted for its role in energy and anti-aging.

Beyond peptides, Hims & Hers will offer compounded versions of essential nutrients such as vitamin B-12, vital for red blood cell formation, DNA synthesis, and nerve function, and L-carnitine, an amino acid derivative that assists in converting fat into energy. While the FDA has approved certain prescription forms of these compounds for established medical uses, primarily for diagnosed deficiencies, Hims & Hers is targeting a broader wellness and preventative care market.

Looking ahead, Hims & Hers has articulated plans to significantly expand its portfolio of U.S.-made peptides and therapies. This future expansion includes two highly discussed unapproved peptides: BPC-157 and TB-500. BPC-157, derived from a protein found in human gastric juice, is marketed for its potential healing processes. TB-500, originating from a naturally occurring protein in the body, is promoted for broader, systemic soft-tissue recovery and flexibility. It is important to note that the vast majority of research on both BPC-157 and TB-500 has been conducted in animal models, with limited human trials to substantiate their efficacy and safety in humans. The company’s strategic foresight is also evident in its acquisition of a California-based peptide manufacturing facility equipped with advanced synthesizers, an acquisition slated to finalize in February 2025, signaling a long-term commitment to this market segment.

The Telehealth Model: Access and Oversight

Hims & Hers’ established telehealth model will be central to the delivery of these new treatments. Prospective members seeking peptide products will undergo an initial assessment involving a review of their health history and personal goals. This assessment will be conducted by a licensed provider specifically trained in peptide therapies, who will then, if deemed appropriate, tailor a personalized treatment plan. The company emphasizes its commitment to ongoing patient engagement, utilizing its communication platform to check in with patients and monitor their progress. Dr. Anant Vinjamoori, Hims’ chief medical officer, elaborated on this approach, stating, "If they’re not [seeing desired results], we need to do something about it. We need to, you know, adjust the dose when that’s appropriate, or in some cases consider other compounds that’s maybe a better fit. And of course, there will also be cases when we need to refer people to other care options."

Dr. Vinjamoori also reiterated the company’s awareness of the data gaps, acknowledging, "We don’t have all of this data that we’re used to having with compounds like this." He framed this as an "opportunity to get it right" and a "responsibility with a company of our size, our skill, and resources to really lead." He also clarified that individuals with serious pre-existing conditions, such as cardiovascular disease, liver disease, and kidney disease, would not be candidates for these compounds at this time, indicating a cautious approach to patient selection.

Adding significant weight to Hims & Hers’ entry into this space is the recent addition of Dr. Andrew Huberman to its board of directors. Huberman, a renowned neuroscientist, popular podcaster, and Stanford University School of Medicine professor, issued a statement calling these compounds "real medical treatments, not just a wellness trend." He lauded Hims for providing "safe access through trusted sourcing and physician oversight," aiming to legitimize the use of these substances within a medical framework. The company also states that patients utilizing its peptide and longevity products can opt for its "Care+" offering, which includes ongoing support, twice-yearly lab testing to track progress, and 24/7 access to messaging providers trained in peptide therapy.

Expert Concerns and the Evidence Gap

Despite Hims & Hers’ assurances and structured approach, health experts have voiced considerable concerns regarding the broader mainstream marketing of unapproved peptides in the U.S., particularly their accessibility through telehealth platforms. Joshua Kritzer, a chemistry professor at Tufts University, urged caution, stating, "With peptides, I think you have to view them the same way you would view any drug that hasn’t been rigorously tested." He stressed that without rigorous testing, reliance on anecdotal information is insufficient for substances intended for human consumption. Kritzer highlighted the critical absence of large-scale clinical trials, which prevents researchers from identifying potentially serious, rare complications – the very risks that have led regulators to reject or withdraw otherwise effective drugs after comprehensive human testing.

Paul Knoepfler, a cell biology and human anatomy professor at UC Davis Health, echoed these concerns, particularly regarding dosing. He pointed out that without robust clinical trials, it is unclear how telehealth firms, physicians, and pharmacies can reliably determine appropriate dosages for patients. While some practitioners may rely on anecdotal data, Knoepfler emphasized that "the dosing for these products really has not been established." He warned of potential risks, including "weird immune responses that are really bad for one’s health" if the body perceives synthetic peptides as foreign substances. Knoepfler’s perspective underscores the "loosey-goosey" nature of peptide administration without established scientific guidelines. While he acknowledged that more physician contact with patients taking compounded peptides is beneficial, he insisted that providers must thoroughly inform patients about potential risks, unknowns, and consider their medical history, including cancer and other medications.

The evidence base for the efficacy of specific peptides remains highly variable and, in many cases, thin or non-existent for the broad wellness claims being made. For instance, a 2026 systematic review that screened 113 studies, encompassing both small human trials and rodent research on NAD+, found zero eligible clinical outcome trials definitively proving that administering intravenous (IV) or intramuscular NAD+ improves anti-aging, energy, or general wellness endpoints in humans.

Regarding L-carnitine, a review of 37 trials did indicate that participants lost an average of about 2.7 pounds, suggesting some potential for weight management. However, this analysis does not directly demonstrate that a compounded injection, as offered by Hims, would yield the same results or that it is appropriate for individuals without a diagnosed deficiency. Similarly, vitamin B-12 injections are predominantly prescribed for individuals with diagnosed deficiencies, a condition that U.S. survey data suggests affects only about 3.6% of adults, rather than for general preventative care or energy boosts in the general population.

The evidence for glutathione is particularly weak for its widely marketed uses. Despite its popularity for skin whitening, IV injections of glutathione are not FDA-approved for this purpose. A small study published in the Journal of Pakistan Association of Dermatologists evaluating IV glutathione concluded that the treatment was "not very effective" for skin-lightening and that its efficacy diminished over time. Furthermore, in August, the FDA reported receiving at least 30 adverse event reports from patients who had received compounded IV glutathione, either alone or in combination with other ingredients, from various compounding pharmacies. Investigations revealed that some of the glutathione tied to these reports was labeled as "dietary supplement grade," which is inappropriate for injectable drugs, and some products contained elevated endotoxin levels, leading to recalls by Texas pharmacies. While these studies and reports do not directly assess Hims & Hers’ specific formulations, they powerfully highlight the current limitations of data, the questions surrounding efficacy, and the potential safety concerns associated with compounded glutathione.

Broader Impact and Implications

Hims & Hers’ entry into the unapproved peptide market represents a significant moment in the evolving landscape of telehealth, wellness, and longevity. It underscores a growing trend where consumer demand for health optimization and anti-aging solutions outpaces the pace of traditional drug approval processes. By leveraging a nuanced regulatory policy, Hims & Hers is positioning itself as a leader in a potentially lucrative, yet scientifically ambiguous, market.

The implications are multi-faceted. For consumers, it offers increased access to compounds previously available through less regulated channels, potentially with greater physician oversight than black-market alternatives. However, it also presents the challenge of making informed decisions about substances lacking comprehensive clinical data, with the potential for unforeseen risks and unproven benefits. The company’s commitment to patient assessment and ongoing support aims to mitigate some of these concerns, yet the fundamental lack of robust human trials for many of these peptides remains a critical point of contention among medical experts.

For the pharmaceutical and healthcare industries, this move by a prominent telehealth company could set a precedent, encouraging other players to explore similar ventures in regulatory grey areas. It also intensifies the debate around the role of compounding pharmacies, the scope of telehealth prescriptions for unapproved substances, and the need for clearer, more comprehensive regulatory frameworks for novel wellness and longevity treatments. The future trajectory of Hims & Hers’ Peptides+ platform will undoubtedly be closely watched by regulators, medical professionals, and consumers alike, as it navigates the complex interplay between innovation, consumer demand, and scientific rigor in the quest for health and longevity.

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *